Active Ingredient History
Ketotifen is a cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis. Ketotifen was developed in 1970 by Sandoz Pharmaceuticals of Switzerland. It is a benzocycloheptathiophene derivative and was initially marketed as an inhibitor of anaphylaxis. The pharmacodynamic properties of ketotifen are many, because it is an inhibitor of the release and/or activity of mast cell and basophil mediators, including histamine, neutrophil, and eosinophil chemotactic factors, arachidonic acid metabolites, prostaglandins, and leukotrienes. Properties of ketotifen which may contribute to its antiallergic activity and its ability to affect the underlying pathology of asthma include inhibition of the development of airway hyper-reactivity associated with activation of platelets by PAF (Platelet Activating Factor), inhibition of PAF-induced accumulation of eosinophils and platelets in the airways, suppression of the priming of eosinophils by human recombinant cytokines and antagonism of bronchoconstriction due to leukotrienes. Ketotifen is marketed under many brand names worldwide. Ketotifen inhibits the release of mediators from mast cells involved in hypersensitivity reactions. Decreased chemotaxis and activation of eosinophils have also been demonstrated. Ketotifen also inhibits cAMP phosphodiesterase. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Conjunctivitis, Allergic (approved 2006)
Allergy and Immunology (Phase 2)
Asthma (Phase 4)
Chronic Pain (Phase 1/Phase 2)
Conjunctivitis (Phase 4)
Conjunctivitis, Allergic (Phase 3)
Contracture (Phase 2)
COVID-19 (Phase 3)
Dengue (Phase 4)
Dermatitis (Phase 3)
Dermatitis, Atopic (Phase 3)
Dyspepsia (Phase 3)
Elbow (Phase 3)
Fibromyalgia (Phase 3)
Fractures, Bone (Phase 3)
Liver Diseases (Phase 4)
Peripheral Nervous System Diseases (Phase 3)
Pleural Effusion (Phase 4)
Rhinitis, Allergic, Perennial (Phase 3)
ST Elevation Myocardial Infarction (Phase 4)
Visual Acuity (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
